Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative - Fierce Pharma
Fierce Pharma reports on Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative in Science & Health.
Take A Coffee NEWS Staff··2 min read
Fierce Pharma reported Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative. Take A Coffee NEWS is tracking the story on the Science & Health desk for readers following medicine, public health, research, climate, space, and science policy.
Source
Why it matters
The story belongs in this desk because it may affect readers tracking medicine, public health, research, climate, space, and science policy.